GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/VS System for diagnosing early gastric cancer

VS System for diagnosing early gastric cancer

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated August 1, 2025

Quick Answer

### **VS Classification System for Diagnosing Early Gastric Cancer** The **VS Classification System** is a standardized diagnostic approach designed to detect **early gastric cancer (EGC)** using **Narrow Band Imaging (NBI)**, a specialized endoscopic imaging technology. This system enhances the visualization of mucosal and vascular changes in the stomach lining, enabling precise and early detection of cancerous lesions.


### **VS Classification System for Diagnosing Early Gastric Cancer**

The **VS Classification System** is a standardized diagnostic approach designed to detect **early gastric cancer (EGC)** using **Narrow Band Imaging (NBI)**, a specialized endoscopic imaging technology. This system enhances the visualization of mucosal and vascular changes in the stomach lining, enabling precise and early detection of cancerous lesions.

---

### **Key Components of the VS Classification System**

The VS system is based on the evaluation of two critical features:

1. **Vascular Pattern (V)**

2. **Surface Pattern (S)**

These features are assessed using **magnifying endoscopy with NBI**, which provides high-resolution images of the stomach's mucosal and submucosal layers.

#### **1. Vascular Pattern (V)**

  • **Irregular Microvascular Architecture**:
  • Distorted, tortuous, or dilated capillary structures.
  • Loss of normal vascular symmetry and organization.
  • **Demarcation Line**:
  • A clear boundary separating abnormal vascular patterns from surrounding normal mucosa.
  • **Corkscrew Vessels**:
  • Abnormal, twisted vessels often seen in early gastric cancer, indicative of neoplastic changes.

#### **2. Surface Pattern (S)**

  • **Irregular Microsurface Structure**:
  • Loss of normal pit patterns.
  • Presence of irregular, ridged, or nodular mucosal surface architecture.
  • **White Zone Changes**:
  • Areas of abnormal light reflection, suggesting mucosal damage or cancerous transformation.

---

### **Diagnostic Criteria**

Early gastric cancer (EGC) is suspected when:

1. **Vascular Pattern**:

  • Irregular microvascular architecture is observed.
  • A distinct **demarcation line** separates the lesion from normal mucosa.

2. **Surface Pattern**:

  • Irregular microsurface structure is present.
  • **White zone changes** are visible.

When **both vascular and surface irregularities** are identified, the likelihood of EGC is significantly increased.

---

### **Clinical Applications**

1. **Targeted Biopsy**:

  • The VS system helps identify suspicious areas for biopsy, improving diagnostic accuracy and reducing unnecessary biopsies.

2. **Endoscopic Submucosal Dissection (ESD)**:

  • Lesions diagnosed using the VS system can be resected precisely via ESD, ensuring complete removal with clear margins.

3. **Surveillance**:

  • High-risk patients (e.g., those with chronic atrophic gastritis or intestinal metaplasia) can be monitored using the VS system to detect EGC at an early stage.

---

### **Advantages of the VS Classification System**

1. **High Sensitivity and Specificity**:

  • Improves diagnostic accuracy compared to conventional white light endoscopy (WLE).
  • Sensitivity: ~88%; Specificity: ~75% (depending on study and operator expertise).

2. **Non-Invasive**:

  • NBI is integrated into standard endoscopy systems, eliminating the need for dyes or additional equipment.

3. **Improved Diagnostic Yield**:

  • Enhances the detection of subtle mucosal changes indicative of early gastric cancer.

---

### **Limitations**

1. **Operator Dependence**:

  • Requires expertise in magnifying NBI and familiarity with VS classification patterns.

2. **False Positives**:

  • Inflammatory lesions or benign changes may mimic irregular vascular and surface patterns, leading to potential overdiagnosis.

---

### **Comparison: VS Classification vs White Light Endoscopy (WLE)**

| **Parameter** | **VS Classification (NBI)** | **White Light Endoscopy (WLE)** |

|------------------------------|--------------------------------------|-----------------------------------------|

| **Vascular Visualization** | Enhanced with high contrast | Limited visualization |

| **Surface Architecture** | Detailed microsurface pattern | Poor resolution of surface patterns |

| **Diagnostic Accuracy** | Higher sensitivity and specificity | Lower sensitivity for early lesions |

| **Targeted Biopsy** | Precise biopsy sampling | Random biopsy sampling |

---

### **Clinical Evidence Supporting VS Classification**

1. **Ezoe et al. (2011)**:

  • Demonstrated that magnifying NBI with the VS system was more accurate than WLE for diagnosing gastric mucosal cancer.
  • Sensitivity: 88%; Specificity: 75%.

2. **Zhang et al. (2016)**:

  • A meta-analysis showed that NBI combined with the VS classification significantly improved diagnostic efficacy for EGC.

3. **Dinis-Ribeiro et al. (2017)**:

  • Prospective studies confirmed that the VS system reduces unnecessary biopsies while maintaining high diagnostic accuracy.

---

### **Future Directions**

1. **Artificial Intelligence (AI)**:

  • AI algorithms are being developed to automate the VS classification process, reducing operator dependency and enhancing diagnostic precision.

2. **Training Programs**:

  • Structured training for endoscopists to improve proficiency in recognizing VS patterns and using NBI technology.

3. **Expansion to Other GI Cancers**:

  • The VS classification system may be adapted for diagnosing other gastrointestinal cancers, such as esophageal or colorectal neoplasms.

---

### **Summary**

The **VS Classification System** is a powerful tool for diagnosing **early gastric cancer (EGC)** using **Narrow Band Imaging (NBI)**. By evaluating **vascular patterns** (irregular microvascular architecture, demarcation line) and **surface patterns** (irregular microsurface structure, white zone changes), the system provides high sensitivity and specificity for early cancer detection. It facilitates **targeted biopsies**, improves diagnostic accuracy, and supports precise therapeutic interventions like **endoscopic submucosal dissection (ESD)**. Despite its operator dependency, the VS system represents a significant advancement in endoscopic imaging, offering the potential for earlier detection and better outcomes in gastric cancer management.

Related Q&A

EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...

Immediate Endoscopic Necrosectomy in Necrotizing Pancreatitis: Gastroenterology | July 2026

Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...

Endoscopy After Bevacizumab Appears Safe: GIE | July 2026

Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...

Colorectal ESD Perforation: Endoscopy | July 2026

Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer